Merlion Pharmaceuticals is a biotechnology company dedicated to the development of innovative antibiotics aimed at addressing the growing threat of bacterial infections in both humans and animals. The company operates in the pharmaceutical and biotechnology sector, focusing on creating solutions for complex urinary tract infections (cUTI), ear infections, and biodefense against biothreat agents. Merlion's business model revolves around research and development, clinical trials, and regulatory approvals to bring their antibiotic candidates to market. Revenue is generated through the commercialization of approved drugs, partnerships with defense agencies, and collaborations with healthcare institutions. Key clients include hospitals, veterinary clinics, and government defense agencies. The company has achieved significant milestones, including US FDA and Health Canada approval for their finafloxacin-based treatments. Merlion's strategic partnerships, such as with the UK Defence Science and Technology Laboratory and the US Defense Threat Reduction Agency, further bolster their market position.

Keywords: antibiotics, bacterial infections, cUTI, ear infections, biodefense, finafloxacin, FDA approval, veterinary health, clinical trials, biotechnology.